BMS’s Opdivo and Yervoy colorectal cancer trials show promising results
BMS presented this data supporting the use of immune checkpoint inhibitors (ICIs) in combination in patients with newly diagnosed advanced colorectal cancer subtypes at the ASCO Gastrointestinal Cancer Symposium. Credit: Tada Images / Shutterstock. On January 22, BMS announced encouraging findings from the CheckMate -8HW clinical trial, showing that the combination of Opdivo (nivolumab) and […]
BMS’s Opdivo meets co-primary endpoint in colorectal cancer trial
Despite Opdivo’s success in combination trials, Bristol-Myers Squibb faces challenges as Opdivo’s European and U.S. patents expire in 2026 and 2028, respectively, threatening sales growth. There is. Credit: Dennis Diatel, via ShutterStock. Bristol-Myers Squibb (BMS) announced that its Phase III CheckMate-8HW study of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of metastatic […]